Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Geraldine Jeudy
Based on 3 articles published since 2009
(Why 3 articles?)
||||

Between 2009 and 2019, G. Jeudy wrote the following 3 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline [Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]. 2018

Guillot, B / Charles, J / Jeudy, G / Cupissol, D / Dupuy, A / Dutriaux, C / Gangloff, D / Magne, N / Mirabel, X / M'Sadek, A / Pracht, M / Sichel, C / Do Outeiro, G. ·Département de dermatologie, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier, France. Electronic address: b-guillot@chu-montpellier.fr. · CHU de Grenoble, 38700 Grenoble, France. · CHU de Dijon, 21000 Dijon, France. · Institut du Cancer de Montpellier, 34298 Montpellier, France. · CHU de Rennes, 35000 Rennes, France. · CHU de Bordeaux, 33000 Bordeaux, France. · Institut universitaire du cancer de Toulouse, 31100 Toulouse, France. · Institut de cancérologie de la Loire, 42270 Saint-Priest-en-Jarez, France. · Centre Oscar-Lambret, 59000 Lille, France. · Centre Eugène-Marquis, 35000 Rennes, France. · 13470 Carnoux en Provence, France. · Institut national du cancer de Boulogne-Billancourt, 92100 Boulogne-Billancourt, France. ·Ann Dermatol Venereol · Pubmed #29703640.

ABSTRACT: -- No abstract --

2 Article Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients. 2014

Mignot, Grégoire / Hervieu, Alice / Vabres, Pierre / Dalac, Sophie / Jeudy, Geraldine / Bel, Blandine / Apetoh, Lionel / Ghiringhelli, François. ·INSERM, UMR866, Dijon, France; Faculté de Médecine, Université de Bourgogne, Dijon, France. · INSERM, UMR866, Dijon, France; Faculté de Médecine, Université de Bourgogne, Dijon, France; Service de Dermatologie, Centre Hospitalier Universitaire le Bocage, Dijon, France. · Faculté de Médecine, Université de Bourgogne, Dijon, France; Service de Dermatologie, Centre Hospitalier Universitaire le Bocage, Dijon, France. · Service de Dermatologie, Centre Hospitalier Universitaire le Bocage, Dijon, France. · INSERM, UMR866, Dijon, France; Faculté de Médecine, Université de Bourgogne, Dijon, France; Oncologie médicale, Centre Georges François Leclerc, Dijon, France. ·PLoS One · Pubmed #25170840.

ABSTRACT: BACKGROUND: The importance of immune responses in the control of melanoma growth is well known. However, the implication of these antitumor immune responses in the efficacy of dacarbazine, a cytotoxic drug classically used in the treatment of melanoma, remains poorly understood in humans. METHODS: In this prospective observational study, we performed an immunomonitoring of eleven metastatic or locally advanced patients treated with dacarbazine as a first line of treatment. We assessed by flow cytometry lymphoid populations and their activation state; we also isolated NK cells to perform in vitro cytotoxicity tests. RESULTS: We found that chemotherapy induces lymphopenia and that a significantly higher numbers of naïve CD4+ T cells and lower proportion of Treg before chemotherapy are associated with disease control after dacarbazine treatment. Interestingly, NK cell cytotoxicity against dacarbazine-pretreated melanoma cells is only observed in NK cells from patients who achieved disease control. CONCLUSION: Together, our data pinpoint that some immune factors could help to predict the response of melanoma patients to dacarbazine. Future larger scale studies are warranted to test their validity as prediction markers.

3 Minor Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis. 2015

Jeudy, G / Dalac-Rat, S / Bonniaud, B / Hervieu, A / Petrella, T / Collet, E / Vabres, P. ·Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France. geraldine.jeudy@chu-dijon.fr. · Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France. · Service d'Anatomie Pathologique, Centre Hospitalier Universitaire, 21000, Dijon, France. ·Br J Dermatol · Pubmed #25384395.

ABSTRACT: -- No abstract --